Skip to main content

Portage Biotech, Inc. (PRTG)

NASDAQ: PRTG · IEX Real-Time Price · USD
19.06 0.56 (3.03%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap254.00M
Revenue (ttm)n/a
Net Income (ttm)-19.76M
Shares Out12.21M
EPS (ttm)-1.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,526
Open18.71
Previous Close18.50
Day's Range18.23 - 19.18
52-Week Range13.40 - 44.98
Beta133.53
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About PRTG

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, ...

IndustryBiotechnology
Founded1973
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolPRTG
Full Company Profile

Financial Performance

Financial Statements

News

Portage Biotech Announces Participation in September 2021 Investor Conferences

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and...

1 month ago - GlobeNewsWire

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

- $29 million raised during quarter with broad institutional support

1 month ago - GlobeNewsWire

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small...

WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targ...

2 months ago - GlobeNewsWire

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021

-  Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets -  Additional clinical mile...

2 months ago - GlobeNewsWire

Portage Biotech Added to Russell 2000(R) Index

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapi...

3 months ago - Newsfile Corp

Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares

Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapie...

4 months ago - Newsfile Corp

Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares

Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapie...

4 months ago - Newsfile Corp

Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ...

- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to si...

4 months ago - Newsfile Corp

Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange

Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG"Westport, Connecticut--(Newsfile Corp. - April 16, 2021) -  Portage Biotech Inc.,...

6 months ago - Newsfile Corp

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive ...

- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to impro...

6 months ago - Newsfile Corp

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensi...

- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months...

6 months ago - Newsfile Corp